Biomarker Considerations Before Starting Oral Semaglutide Baseline fasting glucose, insulin resistance, inflammatory markers, and thyroid function provide critical context for GLP-1 tablet response
Multiple clinical studies have confirmed semaglutides effectiveness, showing an average reduction of approximately 10% or greater in total body weight for individuals receiving treatment over several months to a year

Imaging and surgical proof for gallbladder disease are just as crucial as a clear exposure timeline. Because manufacturers often argue that rapid weight loss alone caused gallbladder issues, your legal team must establish a clear chain of causation supported by various forms of evidence, including: Pharmacy records identifying the specific brand, dosage, and duration of GLP-1 use Imaging results such as ultrasound, CT, or HIDA scans confirming gallstones or gallbladder inflammation Hospital and surgical records including ER notes, admission summaries, and operative and pathology reports Physician statements noting the absence of prior gallbladder conditions and linking the onset of symptoms to drug exposure Personal timeline showing when symptoms began, how they affected work, and any lasting dietary or digestive issues Our attorneys can review all relevant evidence to establish a clear connection between the medication and your injury

The dosage makes it easy to titrate upward to 1,000mg or 1,500mg, as well, should you need to